Aldose reductase inhibition: Emerging drug target for the treatment of cardiovascular complications

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 1, 2010, Pages 25-32

  Reddy, Aramati B M ^a   Ramana, Kota V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Aldose reductase; Cardiovascular Ischemia; Diabetes; Inflammation; Oxidative stress; Polyol

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; FIDARESTAT; RANIRESTAT; ZENARESTAT;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATARACT; CELL HYPERPLASIA; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; HEART MUSCLE ISCHEMIA; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REPERFUSION INJURY; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER;

ALDEHYDE REDUCTASE; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PATENTS AS TOPIC;

EID: 77950158331     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010790192683     Document Type: Review

References (98)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Notkins AL. Immunologic and genetic factors in type 1 diabetes. J Biol Chem 2002; 277: 43545-142548
3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
4. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
5. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 41: 1387-1393. (Pubitemid 36439001)
6. Yan S, Ramasamy S, Bucciarelli LG, et al. RAGE and its ligands: A lasting memory in diabetic complications? Diab Vasc Dis Res 2004; 1: 10-20.
7. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2004; 54: 1615-1625. (Pubitemid 40770750)
8. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005; 26: 380-392. (Pubitemid 40691299)
9. Hers HG. The mechanism of the transformation of glucose in fructose in the seminal vesicles. Biochem Biophys Acta 1956; 22: 202-203.
10. van Heyningen R. Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 1959; 468: 194-195.
11. Bruno S, Cattaneo D, Perico N, Remuzzi G. Emerging drugs for diabetic nephropathy. Expert Opin Emerg Drug 2005; 10: 747-771.
12. Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004; 3: 245-255. (Pubitemid 38924091)
13. Ramirez MA, Borja NL. Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008; 28: 646-655. (Pubitemid 351620031)
14. Ramana KV, Tammali R, Reddy AB, Bhatnagar A, Srivastava SK. Aldose reductase-regulated tumor necrosis factor-alpha production is essential for high glucose-induced vascular smooth muscle cell growth. Endocrinology 2007; 148: 4371-4384. (Pubitemid 47295687)
15. Reddy AB, Ramana KV, Srivastava S, Bhatnagar A, Srivastava SK. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells. Endocrinology 2009; 150: 63-74.
16. Ramana KV, Bhatnagar A, Srivastava SK. Aldose reductase regulates TNF-alpha-induced cell signaling and apoptosis in vascular endothelial cells. FEBS Lett 2004; 570: 189-194. (Pubitemid 38900980)
17. Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chalack LT. Direct measurement of polyol pathway activity in the ocular lens. Diabetes 1984; 33: 196-199. (Pubitemid 14184708)
18. Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 1995; 92: 2780-2784.
19. Srivastava SK, Ansari NH. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. Diabetes 1988; 37: 1505-1508.
20. Ansari NH, Srivastava SK. Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochem Biophys Res Commun 1990; 168: 939-1933
21. Ansari NH, Bhatnagar A, Fulep E, Khanna P, Srivastava SK. Trolox protects hyperglycemia-induced cataractogenesis in cultured rat lens. Res Commun Chem Pathol Pharmacol 1994; 84: 93-104. (Pubitemid 24127656)
22. Srivastava, S.K, Ramana, K.V.: US20070021366 (2007).
23. Mylari, B.L.: US7572910 (2009).
24. Martin, W.H., Mylari, B.L: US6730674 (2004).
25. Jonas, M., Vaulont, I., Soi, A., Schmidt, G.: US7582796 (2009).
26. Richard, R.: US7410659 (2008).
27. Srivastava, S.K., Ramana, K.V., Bhatnagar, A.: US20060293265 (2006).
28. Neogi, P., Dey, D., Medicheria, S., Nag, B., Lee, A.: US7407978 (2008).
29. Yoshikawa, M., Matsuda, H., Yamagishi, M., Matsumoto, H.: US20070060533 (2007).
30. Mylari, B.L.: US20040198740 (2004).
31. Mylari, B.L.,: US6849629 (2005).
32. Drell VR, Pacher P, Ali TK, et al. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative- nitrosative stress, glial activation, and apoptosis. Int J Mol Med 2008; 21: 667-676.
33. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990; 108: 1301-1309. (Pubitemid 20295393)
34. Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opinion Invest Drug 2008; 575-581. (Pubitemid 351578174)
35. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care 2001; 24: 1776-1782.
36. Kang ES, Kim HJ, Paek KS, et al. Phorbol ester up-regulates aldose reductase expression in A549 cells: A potential role for aldose reductase in cell cycle modulation. Cell Mol Life Sci 2005; 62: 1146-1155.
37. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the sprague dawley rat. Diabetologia 1995; 38: 387-394.
38. Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes 2006; 55: 901-910. (Pubitemid 44100162)
39. Wight T. The extracellular matrix and atherosclerosis. Curr Opin Lipidol 1995; 6: 326-334.
40. Newby AC, Alla B. Molecular mechanisms in intimal hyperplasia. J Pathol 2000; 190: 300-309.
41. Kim H, Cho H, Cho H, et al. The essential role of p21 in radiation-induced cell cycle arrest of vascular smooth muscle cell. J Mol Cell Cardiol 2004; 37: 871-880.
42. Bruemmer D, Law RE. Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med 2003; 115: 87-92.
43. Willis AI, Pierre-Paul D, Sumpio BE, Gahtan V. Vascular smooth muscle cell migration: Current research and clinical implications. Vasc Endovasc Surg 2004; 38: 11-23.
44. Schwartz SM, deBlois D, O'Brien ER. The intima: Soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-465.
45. Bahorun T, Soobrattee MA, Luximon-Ramma V, Aruoma OI. Free radicals and antioxidants in cardiovascular health and disease. Int J Med Update 2006; 1: 25-41.
46. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
47. Serrano CV, Ramires JAF, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29: 1276-1283.
48. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-1803.
49. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
50. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2002; 30; 277: 32063-32070.
51. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 2004; 53: 2910-2920.
52. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Srivastava SK. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 2005; 54: 818-829.
53. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
54. Uchida K. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog Lipid Res 2003; 42: 318-343.
55. Pryor WA, Porter NA. Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radic Biol Med 1990; 8: 541-543.
56. Srivastava S, Dixit BL, Cai J, et al. Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radic Biol Med 2000; 29: 642-651.
57. Srivastava S, Conklin DJ, Liu SQ, et al. Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells. Atherosclerosis 2001; 158: 339-350.
58. Ramana KV, Bhatnagar A, Srivastava S, et al. Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): Role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth. J Biol Chem 2006; 281: 17652-17660.
59. Ramana KV, Dixit BL, Srivastava S, Balendiran GK, Srivastava SK, Bhatnagar A. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 2000; 39: 12172-12180.
60. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1998; 68: 1905-1912.
61. Pasupathy S, Homer-Vanniasinkam S. Ischaemic preconditioning protects against ischaemia/reperfusion injury: emerging concepts. Eur J Vasc Endovasc Surg 2005; 29: 106-115.
62. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-588.
63. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005; 14: 170-175.
64. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
65. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. J Am Coll Cardiol 1993; 22: 1788-1794.
66. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. Circulation 1996; 94: 1818-1825.
67. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation 2004; 109: 476-480.
68. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-1436.
69. Sahara M, Kirigaya H, Oikawa Y, et al. Soft plaque detected on intravascular ultrasound is the strongest predictor of in-stent restenosis: An intravascular ultrasound study. Eur Heart J 2004; 25: 2026-2033.
70. Vedder NB, Harlan JM. Increased surface expression of CD11b/CD18 (Mac-1) is not required for stimulated neutrophil adherence to cultured endothelium. J Clin Invest 1988; 81: 676-682.
71. Masuda M, Murakami T, Egawa H, Murata K. Decreased fluidity of polymorphonuclear leukocyte membrane in streptozocin-induced diabetic rats. Diabetes 1990; 39: 466-470. (Pubitemid 20111430)
72. Freedman SF, Hatchell DL. Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes. Exp Eye Res 1992; 55: 767-773.
73. Lo SK, Detmers PA, Levin SM, Wright SD. Transient adhesion of neutrophils to endothelium. J Exp Med 1989; 169: 1779-1793.
74. Julián P, Iwao K, Rodriguez-Vaca MD, et al. Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation 1996; 93: 161-167.
75. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: Key modulator of myocardial ischemic injury. Circulation 2006; 113: 1226-1234.
76. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
77. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). Nat Med 1998; 4: 1025-1031.
78. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
79. Sakaguchi T, Yan SF, Yan SD, et al. Arterial restenosis: Central role of RAGE-dependent neointimal expansion. J Clin Invest 2003; 111: 959-972.
80. Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 2004; 18: 1192-1199. (Pubitemid 39006881)
81. Hwang YC, Sato S, Tsai JY, et al. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 2002; 16: 243-245.
82. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition improves the altered glucose metabolism of isolated diabetic rat hearts. Diabetes 1997; 46: 292-300. (Pubitemid 27272264)
83. Ramasamy R, Trueblood NA, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 1998; 275: H195-H203.
84. Hwang YC, Shaw S, Kaneko M, Redd H, Marerro M, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: A novel axis in myocardial ischemic injury. FASEB J 2005; 19: 795-797. (Pubitemid 40617387)
85. βII. Circ Res 2005; 96: 197-206.
86. Ramana KV, Willis MS, White MD, et al. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 2006; 114: 1838-1846.
87. Reddy AB, Srivastava SK, Ramana KV. Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 2009; 48: 170-176.
88. Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 2003; 10: 1375-1387. (Pubitemid 36903154)
89. Demaine AG. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem 2003; 10: 1389-1398. (Pubitemid 36896566)
90. Watarai A, Nakashima E, Hamada Y, et al. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients. Diabetic Med 2006; 23: 894-899.
91. Makiishi T, Araki S, Koya D, Maeda S, Kashiwagi A, Haneda M. C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 943-951. (Pubitemid 37322911)
92. Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes. Diabetic Med 2004; 21: 1325-1333. (Pubitemid 39620057)
93. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999; 48: 1338-1340. (Pubitemid 29241035)
94. Neamat-Allah M, Feeney SA, Savage DA, et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabet Med 2001; 18: 906-914.
95. Wang Y, Ng MC, Lee SC, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26: 2410-2415.
96. Gosek K, Moczulski D, Zukowska-Szczechowska E, Grzeszczak W. C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control. Nephron Exp Nephrol 2005; 99: E63-E67. (Pubitemid 40470349)
97. Ramana KV, Srivastava SK. Aldose reductase: A novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 2009; doi: 10.1016/j.biocel.2009.09.009. [Epub ahead of print].
98. st century. Curr Med Chem 2009; 16: 734-752.